IndustryCompany release

Charles River lifts 2026 guidance after 4.7% organic revenue growth in third quarter

🇺🇸 Charles River Laboratories International, Inc. (CRL) · Wed 04 Nov 2026

The preclinical contract research group reported Q3 revenue of $982.7 million, down 2.2% as reported after divestitures, and raised its full-year revenue and non-GAAP earnings outlook.

Charles River Laboratories International reported results for the quarter ended 26 September 2026 on 4 November, posting revenue of $982.7 million. That was 2.2% lower than a year earlier on a reported basis, a decline the company attributed to divestitures.

Stripping out those disposals, organic revenue rose 4.7%. Growth was led by the Discovery and Safety Assessment (DSA) segment and the Manufacturing segment, according to the company's summary of the results.

Non-GAAP earnings per share came to $3.09 for the quarter. On the back of the performance, Charles River raised its 2026 guidance for both revenue and non-GAAP earnings per share. The summary available does not give the new guidance ranges, so they are not reproduced here.

The company also noted a collaboration with the US Food and Drug Administration to validate preclinical tools for screening abuse potential. No further detail on the scope, timing or methods involved was available in the material reviewed.

What it means for your team

  • Organic growth in DSA suggests continued demand for outsourced preclinical safety work, which may be relevant to sponsors planning study capacity.
  • The FDA collaboration on validating preclinical abuse-potential screening is worth monitoring by teams working on CNS and other drugs that require abuse-liability assessment.
  • Divestitures account for the gap between reported and organic revenue, so year-on-year comparisons should be made with care.

Company's press release (SEC filing): Charles River Laboratories International, Inc. ↗

Article written by VigiEye from the official source (Charles River Laboratories International, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →